Cytokinetics(US:CYTK) Newsfileยท2025-11-16 13:28Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [2][5][7]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][2]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [2]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, expecting FDA approval in the second half of 2025 [5]. - The company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [5][6]. Group 3: Impact on Investors - Following the revelation of the misleading statements, class members purchased Cytokinetics' common stock at inflated prices and subsequently suffered significant losses [7]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [8].